Concerning the tumour–host interaction marker, the assessment of PD-L1 has been mandated by the ESMO guidelines, at least for unresectable cases, due to the growing evidence of improvement in clinical responses to checkpoint inhibition, and not only in advanced NSCLC [12]. This evidence concerns the gene CD274 and neoplasm.